Subscription-Based Pricing for Lenacapavir—Learning From Hepatitis C and Cabotegravir

This Viewpoint discusses ways in which payer license agreements can facilitate widespread lenacapavir use, a key step in ending the HIV epidemic.

Corresponding Author: Michael R. Rose, MD, MPH, Department of Medicine, Division of Clinical Pharmacology, Johns Hopkins University School of Medicine, 601 N Caroline St, Baltimore, MD 21205 (mrose32@jhmi.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.